Literature DB >> 14601750

Nonparametric comparison of two survival-time distributions in the presence of dependent censoring.

A G DiRienzo1.   

Abstract

When testing the null hypothesis that treatment arm-specific survival-time distributions are equal, the log-rank test is asymptotically valid when the distribution of time to censoring is conditionally independent of randomized treatment group given survival time. We introduce a test of the null hypothesis for use when the distribution of time to censoring depends on treatment group and survival time. This test does not make any assumptions regarding independence of censoring time and survival time. Asymptotic validity of this test only requires a consistent estimate of the conditional probability that the survival event is observed given both treatment group and that the survival event occurred before the time of analysis. However, by not making unverifiable assumptions about the data-generating mechanism, there exists a set of possible values of corresponding sample-mean estimates of these probabilities that are consistent with the observed data. Over this subset of the unit square, the proposed test can be calculated and a rejection region identified. A decision on the null that considers uncertainty because of censoring that may depend on treatment group and survival time can then be directly made. We also present a generalized log-rank test that enables us to provide conditions under which the ordinary log-rank test is asymptotically valid. This generalized test can also be used for testing the null hypothesis when the distribution of censoring depends on treatment group and survival time. However, use of this test requires semiparametric modeling assumptions. A simulation study and an example using a recent AIDS clinical trial are provided.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601750     DOI: 10.1111/1541-0420.00059

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  1 in total

1.  Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?

Authors:  James F Troendle; Eric S Leifer; Lauren Kunz
Journal:  Stat Med       Date:  2018-04-29       Impact factor: 2.373

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.